Advertisement

Prolactin and Prolactin Receptors in Tumor Development, Growth and Cellular Functions

  • Paul A. Kelly
  • Jean Djiane
  • Philippe Gandilhon
  • Alzira A. M. Rosa
  • Rene St-Arnaud
Chapter

Abstract

The importance of prolactin (PRL) in the development and growth of the mammary gland and experimental mammary tumors is clearly established. Prolactin, however, does not act alone in its stimulatory action on normal mammary development nor in its role as an initiator or co-inducer of mammary tumors. A number of other hormones such as estrogens, progesterone, glucocorticoids, thyroid hormones, insulin and growth hormone have been shown to be important for full development and action of the mammary gland (21) and are undoubtedly of great importance in the evolution and maintenance of mammary tumors.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arafah BM, Gullino PM, Manni A, Pearson OH. Effect of ovariectomy on hormone receptors and growth of Nnitrosomethylurea-induced mammary tumors in the rat. Cancer Res 40: 4628–4630, 1980.PubMedGoogle Scholar
  2. 2.
    Ascoli M, Puett D. Degradation of receptor bound human chorionic gonadotropin. J Biol Chem 253: 4892–4899, 1978.PubMedGoogle Scholar
  3. 3.
    Auclair C, Kelly PA, Coy DH, Schally AV, Labrie F. Potent inhibitory activity of [D-Leu6, des-Gly-NH210]LHRH ethylamide on LH/hCG and PRL testicular receptor levels in the rat. Endocrinology 101: 1890–1893, 1977.PubMedCrossRefGoogle Scholar
  4. 4.
    Auclair C, Kelly PA, Labrie F, Coy DH, Schally AV. Inhibition of testicular luteinizing hormone receptor levels by treatment with a potent luteinizing hormone-releasing hormone agonist or human chorionic gonadotropin. Biochem Biophys Res Commun 76: 855–862, 1977.PubMedCrossRefGoogle Scholar
  5. 5.
    Banik UK, Givner ML. Ovulation, induction and antifertility effects of an LHRH analog (AY25205) in cycling rats. J Reprod Fertil 44: 87–94, 1975.PubMedCrossRefGoogle Scholar
  6. 6.
    Barnawell EB, A comparative study of the response of mammary tissue from several mammalian species to hormones in vitro. J Exp Zool 160: 189–206, 1965.PubMedCrossRefGoogle Scholar
  7. 7.
    Beattie CW, Corbin A. Pre- and post-coital contraceptive activity of LHRH in the rat. Biol Reprod 16: 333–339, 1977.PubMedCrossRefGoogle Scholar
  8. 8.
    Bergeron JJM, Posner BI, Josefsberg Z, Sikstrom R. Intracellular polypeptide hormone receptors: its demonstration of specific binding sites for insulin and human growth hormone in Golgi fractions isolated from the liver of female rats. J Biol Chem 253: 4058–4066, 1978.PubMedGoogle Scholar
  9. 9.
    Bohnet HG, Gomez F, Friesen HG. Prolactin and estrogen binding sites in the mammary gland of the lactating and non-lactating rat. Endocrinology 101: 1111–1121, 1977.PubMedCrossRefGoogle Scholar
  10. 10.
    Boston Collaborative Drug Surveillance Program, Reserpine and Breast Cancer. Lancet 2: 669–671, 1974.Google Scholar
  11. 11.
    Bott LM, Muhlbock O, Ropcke G. Prolactin and the induction of mammary tumors in mice. Gen Comp Endocrinol 2: 601–603, 1962.Google Scholar
  12. 12.
    Boyns AR, Buchan R, Cole EN, Forrest APM, Griffiths K. Basal prolactin blood levels in three strains of rat with differing incidence of 7,12-dimethylbenz(a)anthracene-induced mammary tumors. Eur J Cancer 9: 169–171, 1973.CrossRefPubMedGoogle Scholar
  13. 13.
    Boyns AR, Cole EN, Griffiths K, Roberts MM, Buchan R, Wilson RG, Forrest APM. Plasma prolactin in breast cancer. Eur J Cancer 9: 99–102, 1973.PubMedCrossRefGoogle Scholar
  14. 14.
    Cassell E, Meites J, Welsch CW. Effects of ergocornine and ergocryptine on growth of 7,12- dimethylbenzanthracene-induced mammary tumors in rats. Cancer Res 31: 1051, 1971.PubMedGoogle Scholar
  15. 15.
    Chan PC, Tsuang J, Head J, Cohen LA. Effects of estradiol and prolactin on growth of rat mammary adenocarcinoma cells in monolayer cultures (39210). Proc Soc Exp Biol Med 151: 362–365, 1976.PubMedCrossRefGoogle Scholar
  16. 16.
    Chen HJ, Bradley CJ, Meites J. Stimulation of carcinogen-induced mammary tumor growth in rats by adrenalectomy. Cancer Res. 36: 1414–1417, 1977.Google Scholar
  17. 17.
    Conn PM, Conti M, Harwood JP, Dufau ML, Catt KJ Internalization of gonadotropin-receptor complex in ovarian luteal cells. Nature 274: 598–600, 1978.PubMedCrossRefGoogle Scholar
  18. 18.
    Corbin A, Beattie CW, Yardley J, Toell TJ. Post-coital contraceptive effects of an agonistic analogue of luteinizing-releasing hormone. Endocr Res Commun 2: 359–376, 1976.CrossRefGoogle Scholar
  19. 19.
    Costlow ME, Buschow RA, McGuire WL. Prolactin receptors in 7,12-dimethylbenz(a)anthracene-induced mammary tumors following endocrine ablation. Cancer Res 36: 3941–3943, 1976.PubMedGoogle Scholar
  20. 20.
    Costlow ME, Gallagher PE, Koseki Y. Prolactin receptors in primary cultures or carcinogen-induced rat mammary tumors. Mol Cell Endocrinol 14: 81–97, 1979.PubMedCrossRefGoogle Scholar
  21. 21.
    Cowie, A.T. Hormonal factors in mammary development and lactation. pp 3–23 in Mammary Cancer and Neuroendocrine Therapy, edited by BA Stoll, Butterworths, London, 1974.Google Scholar
  22. 22.
    Danguy A, Legros N, Heuson-Stiennon JA, Pasteels JL, Atassi G, Heuson JC. Effects of a gonadotropin-releasing hormone (GnRH) analogue (A43818) on 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Histological and Endocrine Studies. Europ J Cancer 13: 1089–1094, 1977.CrossRefGoogle Scholar
  23. 23.
    DeSombre ER, Arbogast LY. Effect of the antiestrogen CI628 on the growth of rat mammary tumors. Cancer Res 34: 1971–19761, 1974.Google Scholar
  24. 24.
    DeSombre ER, Johnson ES, White WF. Regression of rat mammary tumors affected by a gonadoliberin analog. Cancer Res 36: 3930–3933, 1976.Google Scholar
  25. 25.
    DeSombre ER, Kledzik GS, Marshall S, Meites J. Estrogen and prolactin receptor concentrations in rat mammary tumors and response to endocrine ablation. Cancer Res 36: 354–358, 1976.Google Scholar
  26. 26.
    Devinoy E, Houdebine LM, Delouis C. Role of prolactin and glucocorticoids in the expression of casein genes in rabbit mammary gland organ culture. Quantification of casein mRNA. Biochim Biophys Acta 517: 360–366, 1978.PubMedCrossRefGoogle Scholar
  27. 27.
    Di Carlo R, Muccioli G. Prolactin receptor in human mammary carcinoma. Tumori 65: 695–702, 1979.PubMedCrossRefGoogle Scholar
  28. 28.
    Diley WG, Kister SJ. In vitro stimulation of human breast tissue by human prolactin. J Natl Cancer Inst 55: 35–36, 1975.CrossRefGoogle Scholar
  29. 29.
    Djiane J, Clauser H, Kelly PA. Rapid down-regulation of prolactin receptors in mammary gland and liver. Biochem Biophys Res Commun 90: 1371–1378, 1979.PubMedCrossRefGoogle Scholar
  30. 30.
    Djiane J, Durand P. Prolactin-progesterone antagonism in self-regulation of prolactin receptors in the mammary gland. Nature 266: 641–643, 1977.PubMedCrossRefGoogle Scholar
  31. 31.
    Djiane J, Delouis C, Kelly PA. Prolactin receptors in organ culture of rabbit mammary gland: effect of cycloheximide and prolactin. Proc Soc Exp Biol Med 162: 342–345, 1979.PubMedCrossRefGoogle Scholar
  32. 32.
    Djiane J, Durand P, Kelly PA. Evolution of prolactin receptors in rabbit mammary gland during pregnancy and lactation. Endocrinology 100: 1348–1356, 1977.PubMedCrossRefGoogle Scholar
  33. 33.
    Djiane J, Kelly PA, Houdebine LM. Effects of lysosomotropic agents, cytochalasin B and colchicine on the “down-regulation” of prolactin receptors in mammary explants, Mol Cell Endocrinol 18: 87–98, 1980.PubMedCrossRefGoogle Scholar
  34. 34.
    Dubé D, Kelly PA, Pelletier G. Comparative localization of prolactin binding sites in different rat tissues by immunohistochemistry, radioautography and radioreceptor assay. Mol Cell Endocrinol 18: 109–122, 1980.PubMedCrossRefGoogle Scholar
  35. 35.
    Dutta AS, Purr BJA, Giles MB, Valcaccia B, Walpole AL. Potent agonist and antagonist analogues of duliberin containing an azaglycine residue in position 10. Biochem Biophys Res Commun 81: 382–390, 1978.PubMedCrossRefGoogle Scholar
  36. 36.
    Ferland L, Labrie F, Kelly PA, Raynaud JP. Inhibitory effects of RU16117, a potent estrogen antagonist, on the estrous cycle of the rat. Biol Reprod 18: 99–104, 1978.PubMedCrossRefGoogle Scholar
  37. 37.
    Fluckiger, E. Drugs and the control of prolactin secretion, pp. 162–171 in Prolactin and Carcinogenesis, 4th Tenovous Workshop, eds AR Boyns, K Griffiths, Cardiff Wales: Alpha Omega Alpha Publishing, 1972.Google Scholar
  38. 38.
    Furth J. Experimental pituitary tumors. Recent Prog Horm Res 11: 221–255, 1975.Google Scholar
  39. 39.
    Furth J. Prolactin and carcinogenesis. pp. 137–142 in Prolactin and Carcinogenesis: 4th Tenovous Workshop eds AR Boyns, K Griffiths, Alpha Omega Alpha, Cardiff, 1972.Google Scholar
  40. 40.
    Furth J, Clifton KH. Experimental pituitary tumors. pp 460–497 in The Pituitary Gland, eds GW Harris, BT Donovan, vol 2, Butterworths, London, 1966.Google Scholar
  41. 41.
    Gordon P, Carpentier JL, Cohen S, Orci, L. Epidermal growth factor: morphological demonstration of binding, internalization and lysosomal association in human fibroblasts. Proc Natl Acad Sci USA 75: 5025–5029, 1978.CrossRefGoogle Scholar
  42. 42.
    Gullino PM, Pettigrew HN, Grantham FH. N-nitrosomethyl urea as mammary gland carcinogen in rats. J Natl Cancer Inst 54: 401–414, 1975.PubMedGoogle Scholar
  43. 43.
    Hayden TJ, Bonney RC, Forsyth IA. Ontogeny and control of prolactin receptors in the mammary gland and liver of virgin, pregnant and lactating rats. J Endocrinol 80: 259–269, 1979.PubMedCrossRefGoogle Scholar
  44. 44.
    Heinonen OP,, Shapiro S, Tuominen L, Turunen MI. Réserpine use in relation to breast cancer. Lancet 2: 675–677, 1974.PubMedCrossRefGoogle Scholar
  45. 45.
    Herman V, Kalk WJ, de Moor, NG, Levin J. Serum prolactin after chest wall surgery: elevated levels after mastectomy. J Clin Endocrinol Metab 52: 148–151, 1981.PubMedCrossRefGoogle Scholar
  46. 46.
    Heuson JC, Waelbroeck C, Legros N, Gallez G, Robyn C, L’Hermite M. Inhibition of DMBA-induced mammary carcinogenesis in the rat by 2-Br-α-ergocryptine (CB-154), an inhibitor of prolactin secretion and by nafoxidine (U-11,000A), an estrogen antagonist. Gynecol Invest 2: 130–137, 1971/1972.CrossRefGoogle Scholar
  47. 47.
    Hilliard J, Pang CN, Sawyer CH. Effects of luteinizing hormone-releasing hormone in fetal survival in pregnant rabbits. Fertil Steril 27: 421–425, 1976.PubMedCrossRefGoogle Scholar
  48. 48.
    Hobbs JR, Salih H, Flax H, Brander W. Prolactin dependence in human breast cancer. Proc Roy Soc Med 66: 866–867, 1973.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Holcomb HH, Costlow ME, Buschow RA, McGuire WL. Prolactin binding in rat mammary gland during pregnancy and lactation. Biochim Biophys Acta 428: 104–112, 1976.PubMedCrossRefGoogle Scholar
  50. 50.
    Holdaway IM. Personal communication.Google Scholar
  51. 51.
    Holdaway IM, Friesen HG. Correlation between hormone binding and growth response of rat mammary tumor. Cancer Res 36: 1562, 1976.PubMedGoogle Scholar
  52. 52.
    Holdaway IM, Friesen HG. Hormone binding by human mammary carcinoma. Cancer Res 37: 1946–1952, 1977.PubMedGoogle Scholar
  53. 53.
    Houdebine LM, Djiane J. Effects of lysosomotropic agents, microfilament and microtubule disrupting drugs on the actuation of casein gene expression by prolactin in the mammary gland. Mol Cell Endocrinol 17: 1–15, 1980.PubMedCrossRefGoogle Scholar
  54. 54.
    Huggins, C., Grand LC, Brillantes FP. Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppression. Nature (London) 189: 204–207, 1961.CrossRefGoogle Scholar
  55. 55.
    Humphrey RR, Windson BL, Bousley FG, Edgren RA. Antifertility effects of an analog of luteinizing hormone-releasing hormone (LHRH) in rats. Contraception 14: 625–629, 1976.PubMedCrossRefGoogle Scholar
  56. 56.
    Johnson ES, Seely JH, White WF, DeSombre ER. Endocrine-dependent rat mammary tumor regression: use of a gonadotropin-releasing hormone analog. Science 194: 329–330, 1976.PubMedCrossRefGoogle Scholar
  57. 57.
    Jordan VC. Effect of tamoxifen (ICI46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 12: 419–424, 1976.PubMedCrossRefGoogle Scholar
  58. 58.
    Jordan VC, Dowse LJ. Tamoxifen as an anti-tumor agent: effect on estrogen binding. J Endocrinol 68: 297–303, 1976.PubMedCrossRefGoogle Scholar
  59. 59.
    Jordan VC, Jaspan T. Tamoxifen as an anti-tumor agent: oestrogen binding as a predictive test for tumor response. J Endocrinol 68: 453–460, 1976.PubMedCrossRefGoogle Scholar
  60. 60.
    Kelly PA, Asselin J, Caron MG, Labrie F, Raynaud JP. High inhibitory activity of a new antiestrogen, RU16117 (llα-methoxyethinyl estradiol), on the development of dimethylbenz(a)anthracene-induced mammary tumors. Cancer Res. 37: 76–81, 1977.PubMedGoogle Scholar
  61. 61.
    Kelly PA, Asselin J, Caron MG, Labrie F, Raynaud JP. Potent inhibitory effect of a new antiestrogen (RU16117) on the growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. J Natl Cancer Inst 58: 623–628, 1977.PubMedCrossRefGoogle Scholar
  62. 62.
    Kelly PA, Bradley C, Shiu RPC, Meites J, Friesen HG. Prolactin binding to rat mammary tumor tissue. Proc Soc Exp Biol Med 146: 816–819, 1974.PubMedCrossRefGoogle Scholar
  63. 63.
    Kelly PA, Djiane J, De Léan A. Interaction of prolactin with its receptor: dissociation and down-regulation. pp. 173–188, In: Central and Peripheral Regulation of Prolactin Function eds RM MacLeod and U. Sacpagnini, Raven Press, New York, 1980.Google Scholar
  64. 64.
    Kelly PA, Djiane J, De Léan A. Prolactin receptor dissociation and down-regulation, in Advances in Prolactin vol 6, Progress in Reproductive Biology, eds M. L’Hermite and S. Judd, Karger, Basel, Switzerland, in press.Google Scholar
  65. 65.
    Kelly PA, Labrie F, Asselin J. The role of prolactin in tumor development. pp. 157–194 in Influences of Hormones in Tumor Development vol. II, eds JA Kellen, R. Hilf, CRC Press Inc., Boca Raton, Florida, 1979.Google Scholar
  66. 66.
    Kelly PA, Leblanc G, Djiane J. Estimation of total prolactin binding sites after in vitro desaturation. Endocrinology 104: 1631–1638, 1979.CrossRefPubMedGoogle Scholar
  67. 67.
    Kelly PA, Posner BI, Friesen HG. Effects of hypophysectomy, ovariectomy and cycloheximide on specific binding sites for lactogenic hormones in rat liver. Endocrinology 97: 1408–1515, 1975.PubMedCrossRefGoogle Scholar
  68. 68.
    Kennedy BJ, French LA, Peyton WT. Hypophysectomy in advanced breast cancer. N Engl J Med 255: 1165–1172, 1956.PubMedCrossRefGoogle Scholar
  69. 69.
    Kim U. Pituitary function and hormonal therapy of experimental breast cancer. Cancer Res 25: 1146–1161, 1965.PubMedGoogle Scholar
  70. 70.
    Kim U, Furth J. Relation of mammary tumors to mammotrophs. II. Hormone responsiveness of 30-methyl-cholanthrene-induced carcinomas. Proc Soc Exp Biol Med 103: 643–645, 1960.PubMedCrossRefGoogle Scholar
  71. 71.
    Kim U, Furth J. The role of prolactin in carcinogenesis. Vitam Horm (NY) 34: 107–136, 1976.CrossRefGoogle Scholar
  72. 72.
    Kledzik GS, Bradley CJ, Meites J. Reduction of carcinogen-induced mammary cancer incidence in rats by early treatment with hormones or drugs. Cancer Res 34: 2953–2956, 1974.PubMedGoogle Scholar
  73. 73.
    Kledzik GS, Cusan L, Auclair C, Kelly PA, Labrie F. Inhibitory effect of a luteinizing hormone (LH)-releasing hormone agonist on rat ovarian LH and follicle-stimulating hormone receptor levels during pregnancy. Fertil Steril 29: 560–564, 1978.PubMedCrossRefGoogle Scholar
  74. 74.
    Kledzik GS, Cusan L, Auclair C, Kelly PA, Labrie F. Inhibition of ovarian LH and FSH receptor levels by treatment with [D-Ala6, des-Gly-NH210]LHRH ethylamide during the estrous cycle in the rat. Fertil Steril 30: 348–353, 1978.PubMedCrossRefGoogle Scholar
  75. 75.
    Kolata GB Polypeptide hormones: what are they doing in cells. Science 201: 895–897, 1978.PubMedCrossRefGoogle Scholar
  76. 76.
    Labrie F, Auclair C, Cusan L, Kelly PA, Pelletier G, Ferland L. Inhibitory effect of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat. Int J Androl (Suppl 2 ), 303–318, 1978.CrossRefGoogle Scholar
  77. 77.
    Lacassagne A, Duplan JF. Le mécanisme de la cancérisation de la mamelle chez la souris. Considéré d’après les résultats d’expériences au moyen de la réserpine. C R Acad Sci [D] (Paris) 249: 810–812, 1959.Google Scholar
  78. 78.
    Lee C, Oyasu R, Chen C. In vitro interaction of estro- gen and prolactin on hormone-dependent rat mammary tumors. Proc Soc Exp Biol Med 148: 224–226, 1975.PubMedCrossRefGoogle Scholar
  79. 79.
    Leung BS, Sasaki GH. Prolactin and progesterone effect on specific estradiol binding in uterine and mammary tissues in vitro. Biochem Biophys Res Commun 55: 1180–1187, 1973.CrossRefGoogle Scholar
  80. 80.
    Loeb L, Kirtz MM. The effects of transplants of anterior lobe of the hypophysis on the growth of the mammary gland and on the development of mammary gland carcinoma in various strains of mice. Am J Cancer 36: 56–82, 1939.Google Scholar
  81. 81.
    Manni A, Chambers MJ, Pearson OH. Prolactin induces its own receptors in rat liver. Endocrinology 103: 2168–2171, 1978.PubMedCrossRefGoogle Scholar
  82. 82.
    Manni A, Trujilo JE, Pearson OH. Predominant role of prolactin in stimulating the growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Cancer Res 37: 1216–1219, 1977.PubMedGoogle Scholar
  83. 83.
    Masters JRW, Sangster K, Smith, T. II. Hormonal sensitivity of human breast tumors in vitro: pentose-shunt activity. Cancer (Philadelphia) 39: 1978–1980, 1977.CrossRefGoogle Scholar
  84. 84.
    Matusik RJ, Rosen JM. Prolactin induction of casein mRNA in organ culture: a model system for studying peptide hormone regulation of gene expression. J Biol Chem 253: 2343–2347, 1978.PubMedGoogle Scholar
  85. 85.
    Maxfield FR, Willingham MC, Davies DJA, Pastan I. Amines inhibit the clustering of α2-macroglobulin and EGF on the fiberblast cell surface. Nature 277: 66 1663, 1979.Google Scholar
  86. 86.
    McCormic GM, Moon RC. Effects of pregnancy and lactation in growth of mammary tumors induced by 7,12-dimethylbenz(a)anthracene (DMBA). Br J Cancer 19: 160–166, 1965.CrossRefGoogle Scholar
  87. 87.
    McMillin JM, Seal US, Theologides A. Prolactin dynamics following transphenoidal hypophysectomy for metastatic carcinoma of the breast. Cancer (Philadelphia) 39: 2254–2251, 1977.CrossRefGoogle Scholar
  88. 88.
    Meites J. Relation of prolactin to mammary tumorigene- sis and growth in rats. pp. 54–63 in Prolactin and Carcinogenesis: 4th Tenovous Workshop eds AR Boyns and K Griffiths, Alpha Omega Alpha, Cardiff, 1972.Google Scholar
  89. 89.
    Muhlbock O, Boot LM Induction of mammary cancer in mice without the mammary tumor agent by isografts of hypophyses. Cancer Res 19: 402–412, 1959.PubMedGoogle Scholar
  90. 90.
    Nagasawa H. Prolactin: its role in the development of mammary tumors. Med Hypotheses 5: 1117–1121, 1979.CrossRefPubMedGoogle Scholar
  91. 91.
    Nicholson RI, Davies P, Griffiths K. Effects of estra- diol-17β and tamoxifen on nuclear estradiol-17β receptors in DMBA-induced rat mammary tumors. Eur J Cancer 13: 201–208, 1977.PubMedCrossRefGoogle Scholar
  92. 92.
    Pasteels JL, Heuson JC, Heuson-Stiennon J, Legros N. Effects of insulin, prolactin, progesterone and estradiol on DNA synthesis in organ culture of 7,12dimethylbenz(a)anthracene-induced rat mammary tumors. Cancer Res 36, 2162–2170, 1976.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Pearson OH, Llerena O, Llerena L, Molina A, Butler T. Prolactin-dependent rat mammary cancer: a model for man? Trans Assoc Am Physicians 82: 225–238, 1969.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Pearson OH, Murray R, Mozaffarian G, Pensky J Prolactin and experimental breast cancer. pp. 154–157 in Prolactin and Carcinogenesis: 4th Tenovous Workshop, eds AR Boyns and K Griffiths, Alpha Omega Alpha, Cardiff, 1972.Google Scholar
  95. 95.
    Pearson OH, Ray BS. Hypophysectomy in the treatment of metastatic mammary cancer. Am J Surg 99: 544–552, 1960.PubMedCrossRefGoogle Scholar
  96. 96.
    Pelletier G, Cusan L, Auclair C, Kelly PA, Desy L, Labrie F. Inhibition of spermatogenesis in the rat by treatment with [D-Ala6, des-Gly-NH210]LHRH ethylamide. Endocrinology 103: 641–643, 1978.PubMedCrossRefGoogle Scholar
  97. 97.
    Posner BI, Kelly PA, Friesen HG. Induction of a lactogenic receptor in rat liver: influence of estrogen and the pituitary. Proc Natl Acad Sci USA 71: 2407–2410, 1974.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Posner BI, Kelly PA, Friesen HG. Prolactin receptors in rat liver: possible induction by prolactin. Science 187: 57–59, 1975.CrossRefGoogle Scholar
  99. 99.
    Posner BI, Raquidan D, Josefsberg Z, Bergeron JM. Different regulation of insulin receptors in intracellular (Golgi) and plasma membranes from livers of obese and lean mice. Proc Natl Acad Sci USA 75: 3302–3306, 1978.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Quadri SK, Clark JL, Meites J. Effects of LSD, pargyline and haloperidol on mammary tumor growth in rats. Proc Soc Exp Biol Med 142: 22–26, 1973.PubMedCrossRefGoogle Scholar
  101. 101.
    Quadri SK, Kledzik GS, Meites J. Enhanced regression of DMBA-induced mammary cancers in rats by a combination of ergocornine with ovariectomy or high doses of estrogen. Cancer Res 34: 499–501, 1974.PubMedPubMedCentralGoogle Scholar
  102. 102.
    Quadri SK, Meites J. Regression of spontaneous mammary tumors in rats by ergot drugs. Proc Soc Exp Biol Med 138: 999–1001, 1972.CrossRefGoogle Scholar
  103. 103.
    Raynaud JP, Bonne C, Bouton MM, Moguilewski M, Philibert D, Azadian-Boulanger G. Screening for anti-hormones by receptor studies. J Steroid Biochem 6: 615–622, 1975.PubMedCrossRefGoogle Scholar
  104. 104.
    Salih H, Brander W, Flax H, Hobbs JR. Prolactin dependence in human breast cancers. Lancet 2: 1103–1105, 1972.PubMedCrossRefGoogle Scholar
  105. 105.
    Sasaki GB, Leung BS. On the mechanism of hormone action in 7,12-dimethylbenz(a)anthracene-induced mammary tumors. Cancer 35: 645–651, 1975.PubMedCrossRefGoogle Scholar
  106. 106.
    Scatchard G. The attraction of protein from small molecules and ions. Ann NY Acad Sci 51: 660–672, 1949.CrossRefGoogle Scholar
  107. 107.
    Shafie S, Brooks SC. Effect of prolactin on growth and the estrogen receptor level of human breast cancer cells (MCF-7). Cancer Res 37: 792–799, 1977.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Shiu RPC, Friesen HG. Properties of a prolactin receptor from the rabbit mammary gland. Biochem J 140: 301–311, 1974.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Shiu RPC, Friesen HG. Solubilization and purification of a prolactin receptor from the rabbit mammary gland. J Biol Chem 249: 7902–7911, 1974.PubMedGoogle Scholar
  110. 110.
    Shiu RPC, Friesen HG. Blockage of prolactin action by an antiserum to its receptors. Science 192: 259–261, 1976.CrossRefPubMedGoogle Scholar
  111. 111.
    Shiu RPC, Friesen HG. Interaction of cell-membrane prolactin receptor with its antibody. Biochem J 157: 619–626, 1976.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Shiu RPC, Kelly PA, Friesen HG. Radioreceptor assay for prolactin and other lactogenic hormones. Science 180: 968–971, 1973.PubMedCrossRefGoogle Scholar
  113. 113.
    Smith RD, Hilf R, Senior AE. Prolactin binding to dissociated cells from rat mammary tumors and mammary gland. Cancer Biochem Biophys 3: 117–121, 1979.PubMedGoogle Scholar
  114. 114.
    Smithline F, Sherman L, Kolodny HD. Prolactin and breast carcinoma. N Engl J Med 292: 784–792, 1975.PubMedCrossRefGoogle Scholar
  115. 115.
    Teller MN, Stock CC, Hellman L, Mountain IM, Bowie M, Rosenberg BJ, Boyar RM, Budinger JM. Comparative effects of a series of prolactin inhibitors, 17β-estradiol and 2α-methyldihydrotestosterone propionate on growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas. Cancer Res 37: 3932–3938, 1977.PubMedGoogle Scholar
  116. 116.
    Terenius L. Antiestrogens and breast cancer. Eur J Cancer 7: 57–64, 1971.PubMedCrossRefGoogle Scholar
  117. 117.
    Terenius L. Effects of antiestrogens on initiation of mammary cancer in the female rat. Eur J Cancer 7: 65–70, 1971.PubMedCrossRefGoogle Scholar
  118. 118.
    Thompson HJ, Becci PJ, Brown CC, Moon RC. Effect of the duration of retinyl acetate feeding on inhibition of 1-methyl-l-nitrosourea-induced mammary carcinogenesis in the rat. Cancer Res 39: 3977–3980, 1979.PubMedGoogle Scholar
  119. 119.
    Tsai TLS, Katzenellenbogen BS. Antagonism of development and growth of 7,12-dimethylbenz(a)anthraceneinduced rat mammary tumors by the antiestrogen U 23469 and effects on estrogen and progesterone receptors. Cancer Res 37: 1537–1543, 1977.PubMedGoogle Scholar
  120. 120.
    Turcot-Lemay L, Kelly PA. Characterization of estradiol, progesterone and prolactin receptors in nitrosomethylurea-induced mammary tumors and effect of antiestrogen treatment on the development and growth of these tumors. Cancer Res 40: 3232–3240, 1980.PubMedGoogle Scholar
  121. 121.
    Turcot-Lemay L, Kelly PA. Response to ovariectomy of Nnitrosomethylurea-induced mammary tumors in the rat. J Natl Cancer Inst 66: 97–102, 1981.PubMedGoogle Scholar
  122. 122.
    Turcot-Lemay L, Kelly PA. Prolactin receptors in human breast tumors. Submitted.Google Scholar
  123. 123.
    Turcot-Lemay L, Kelly PA. Effect of an LHRH analog on growth and hormone levels in DMBA-induced mammary tumors in the rat. Submitted.Google Scholar
  124. 124.
    Welsch CW, Brown CK, Goodrich-Smith M, Chiusano J, Moon RC Synergistic effect of chronic prolactin suppression and retinoid treatment in the prophylaxis of N-methylN-nitrosourea-induced mammary tumorigenesis in female Sprague-Dawley rats. Cancer Res 40: 3095–3098, 1980.PubMedGoogle Scholar
  125. 125.
    Welsch CW, Clemens JA, Meites J. Effects of multiple pituitary homografts or progesterone on 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats. J Natl Cancer Inst 41: 465–471, 1968.PubMedGoogle Scholar
  126. 126.
    Welsch CW, Jenkins TW, Meites J. Increased incidence of mammary tumors in female rat grafted with multiple pituitaries. Cancer Res 30: 1024–1029, 1970.PubMedGoogle Scholar
  127. 127.
    Welsch CW, Meites J. Effects of reserpine in development of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats. Experientia 26: 1133–1134, 1970.PubMedCrossRefGoogle Scholar
  128. 128.
    Welsch CW, Nagasawa H. Prolactin and murine mammary tumorigenesis: a review. Cancer Res 37: 951–963, 1975.Google Scholar
  129. 129.
    Welsch CW, Nagasawa H, Meites J. Increased incidence of spontaneous mammary tumors in female rats with induced hypothalamic lesions. Cancer Res 30: 2310–2313, 1970.PubMedGoogle Scholar
  130. 130.
    Wilson RG, Buchan R, Roberts MM, Forrest APM, Boyns AR, Cole EN, Griffiths K. Plasma prolactin and breast cancer. Cancer (Philadelphia) 33: 1325–1327, 1974.CrossRefGoogle Scholar
  131. 131.
    Yanai R, Nagasawa H. Inhibition of mammary tumorigenesis by ergot alkaloids and promotion of mammary tumori-genesis by pituitary isograpfs in adreno-ovariectomized mice. J Natl Cancer Inst 48: 715–719, 1972.PubMedGoogle Scholar

Copyright information

© Eden Press Inc. 1982

Authors and Affiliations

  • Paul A. Kelly
  • Jean Djiane
  • Philippe Gandilhon
  • Alzira A. M. Rosa
  • Rene St-Arnaud

There are no affiliations available

Personalised recommendations